Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Scrambler Therapy with Duloxetine-Based Usual Care vs. Duloxetine-Based Usual Care for Chemotherapy-Induced Peripheral Neuropathy
The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form.
Scrambler Therapy with Duloxetine for Chemotherapy-Induced Peripheral Neuropathy
Overview
This study investigates the efficacy of Scrambler therapy combined with duloxetine compared to duloxetine-based usual care in patients with chemotherapy-induced peripheral neuropathy (CIPN). The primary objective is to determine if Scrambler therapy leads to a greater reduction in pain scores at day 35 compared to baseline.
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment, significantly impacting patients' quality of life. Current guidelines recommend duloxetine as the standard treatment for established painful CIPN, but evidence for alternative therapies like Scrambler therapy remains inconclusive. Understanding the effectiveness of these treatments is crucial for improving symptom management in cancer patients.
Data Highlights
No numerical data is provided in the source material.
Key Findings
Scrambler therapy is hypothesized to improve pain scores in CIPN patients compared to duloxetine-based usual care.
The primary endpoint is a 50% reduction in pain scores measured by the BPI-Short Form at day 35.
Inclusion criteria require a minimum average pain score of 4/10 and grade 2 neuropathies.
Duloxetine has been shown effective in treating painful CIPN but not in preventing it.
Current evidence for Scrambler therapy is mixed and not yet endorsed by guidelines.
Clinical Implications
Clinicians should consider the potential benefits of Scrambler therapy as an adjunct to duloxetine for managing CIPN, while remaining aware of the current lack of strong evidence supporting its efficacy. Ongoing assessment of patient pain levels and functional outcomes is essential for optimizing treatment strategies.
Conclusion
The investigation into Scrambler therapy's effectiveness in conjunction with duloxetine may provide new insights into managing CIPN, although further research is needed to establish its clinical utility.
